Prostate cancer (PC) is the second most common cancer in men and is the fifth leading cause of cancer-related deaths among men. Androgen receptor (AR) signaling plays a key role in PC tumor growth and progression, with androgens stimulating PC proliferation and survival. Castration-resistant PC (CRPC) is characterized by increasing levels of prostatespecific antigen or radiographic progression despite androgen-deprivation therapy (ADT). In most patients, castration resistance results from aberrations in AR or the AR signaling pathway. Up to one-third of patients with localized high-risk PC will have disease progression on local therapy and develop CRPC. This review summarizes the key clinical data, including ongoing trials, for hormonal therapies in CRPC and provides an overview of the clinical development of darolutamide, a novel, nonsteroidal AR antagonist currently in phase III development for the treatment of nonmetastatic CRPC and metastatic hormone-sensitive PC. In phase I/II trials, darolutamide has demonstrated a favorable safety profile, antitumor activity, and significant decreases in prostate-specific antigen in patients with metastatic CRPC. In the phase III ARAMIS (NCT02200614; A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of Darolutamide in Men With High-Risk Non-metastatic Castration-Resistant Prostate Cancer) study, metastasisfree survival is being evaluated in men with nonmetastatic CRPC who will receive ADT in combination with darolutamide or placebo. The ARASENS (NCT02799602; A Randomized, Double-Blind, Placebo Controlled Phase III Study of Darolutamide Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer) study is a placebo-controlled trial assessing whether the addition of darolutamide to ADT and docetaxel significantly prolongs overall survival in men with metastatic hormone-sensitive PC.
Introduction

Epidemiology
In 2012, more than 1.1 million men were diagnosed with prostate cancer (PC), and approximately 307,000 died from this disease globally. [1] [2] [3] PC is the second most common cancer in men and the fifth leading cause of cancer-related deaths in this population. 1, 2 The incidence of PC is higher in more developed regions, with rates being the highest in Australia, North America, and parts of Europe, which also have a correspondingly higher prevalence of prostate-specific antigen (PSA) testing. 1, 2, 4 Worldwide, PC accounts for approximately 15% of new cancer cases in men annually. 2 Rates of overall survival (OS) are dependent on disease stage at diagnosis because patients with an earlier diagnosis of PC are less likely to die from the disease. 5 For instance, in the United States, most men (80%) are diagnosed when the disease is still localized and have a 5-year relative survival rate of 100%. 5 In contrast, the 5-year survival rate for men with distant metastasis, which accounts for < 10% of cases at diagnosis, is approximately 29%. 3,5 Survival for patients with metastatic disease is reportedly higher for those participating in clinical trials relative to community practice. 6 
Androgen Receptor (AR) Pathway in Prostate Cancer
ARs promote PC growth by driving the expression of genes involved in growth, differentiation, and survival of PC cells. 7, 8 Androgen-deprivation therapy (ADT) reduces serum testosterone 1 to castration levels, 9 thus depriving PC cells of the signals required for growth and survival. 8, 10 Castration-resistant PC (CRPC), which is characterized by increasing levels of PSA or radiographic progression despite ADT, disease progression, or new metastases, 11 results from aberrations in the AR signaling pathway. 7, 12 There are several proposed mechanisms by which AR signaling might be maintained or reactivated, leading to progression to CRPC, including AR gene amplification and AR protein overexpression, AR gain-of-function mutations, adrenal and intratumoral androgen biosynthesis, ligandindependent AR transactivation, and coactivator overexpression. 13 
Current Management
The appropriate treatment for PC depends on the clinical stage of the disease.
14 ADT is widely used to treat localized disease as an adjuvant to radical treatment or in the management of PSA relapse. 11 About one-third of patients with localized disease will have disease progression while undergoing ADT, leading to CRPC. 15 Because many of these patients will have no detectable metastases on imaging, their disease stage is coined nonmetastatic CRPC (nmCRPC). The receptor activator of nuclear factor kappa-B ligand monoclonal antibody denosumab has been shown to prolong bone metastasis-free survival in patients with nmCRPC by 4.2 months (from 25.2 months with placebo to 29.5 months with denosumab). This benefit was offset by increased toxicity (including osteonecrosis of the jaw and hypocalcemia); however, denosumab is not approved for prevention of metastases. 16 Until recently, there has been an unmet need for agents that can delay the development of metastases in men with nmCRPC. Despite favorable treatment response, almost all patients receiving ADT progress to metastatic CRPC (mCRPC). 13 Treatments for mCRPC include the androgen biosynthesis inhibitor abiraterone, enzalutamide, radium 223 (for patients with bone metastases and no known visceral metastatic disease), boneprotecting agents (denosumab, zoledronate), chemotherapy (ie, docetaxel or cabazitaxel), and immunotherapy (eg, sipuleucel-T). [19] [20] [21] [22] Treatment decision-making for patients with mCRPC is influenced by the presence or absence of visceral metastases, the presence or absence of symptoms, and the performance status of the patient, with some differences between these settings. 23 In patients with metastatic hormone-sensitive PC (mHSPC), data from the CHAARTED (NCT00309985; ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (NCT00268476; The most common adverse events (AEs) that occur with abiraterone treatment are fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, vomiting, upper respiratory infection, cough, and headache. 31 
Enzalutamide
Enzalutamide is a second-generation AR antagonist with high affinity for the ligand binding domain (LBD) of AR. 8 Androgen receptor antagonists bind to target tissues and inhibit androgeninduced activation of ARs, thereby inhibiting the expression of genes responsible for proliferation and tumor growth of PC cells. 8, 32 In the phase III AFFIRM (NCT00974311; A Multina- significantly improved radiographic progression-free survival by 81% (65% vs. 14% at 12 months). 34 In addition to the numerous ongoing clinical trials of enzalutamide in combination with other agents in mCRPC ( Enzalutamide is approved in men with nmCRPC based on the results of PROSPER, a placebo-controlled trial of the efficacy and safety of enzalutamide in 1401 patients with nmCRPC. The metastasis-free survival analysis of PROSPER showed that median time to metastasis-free survival was 22 months longer with enzalutamide versus placebo (median months, 36.6 vs. 14.7 months; P < .0001); median OS was not reached in either group in this analysis, although there was a 20% lower relative risk of death in the enzalutamide group versus placebo group. 18 N ¼ 1860) . The primary outcome is metastasis-free survival, and secondary outcomes include OS. ENZARAD will evaluate the efficacy and safety of enzalutamide versus conventional nonsteroidal anti androgen therapy in patients receiving ADT and radiotherapy (estimated enrollment, N ¼ 800). The primary outcome is OS time, and secondary outcomes include cause-specific survival time, PSA progression-free survival time, and clinical progression-free survival time.
Common AEs associated with enzalutamide treatment include asthenia/fatigue, decreased appetite, hot flush, arthralgia, dizziness/ vertigo, hypertension, headache, and decreased weight. 36 Seizures are uncommon but were reported in a small number of enzalutamide recipients in both phase III trials. with nmCRPC. 17 In SPARTAN, apalutamide was associated with a 70% lower risk of metastasis or death versus placebo (median metastatic-free survival, 40.5 months vs. 16.2 months; P < .001).
Apalutamide treatment also demonstrated significantly longer time to symptomatic progression versus placebo (P < .001). The most common AEs included rash, diarrhea, fatigue, nausea, vomiting, hypertension, and hematuria. 17, 38 These results are consistent with phase II results for apalutamide in men with nmCRPC; the combination of apalutamide plus ongoing ADT showed at least a 50% reduction in PSA in 89% of the enrolled patients. 37 
Darolutamide: Drug Profile Preclinical Data: Mechanism of Action
Darolutamide is a nonsteroidal AR antagonist that has a unique molecular structure that is distinct from other AR antagonists. This synthetic compound consists of a 1:1 mixture of 2 pharmacologically active diastereomers ([S,R]-darolutamide and [S,S]-darolutamide), which interconvert through the pharmacologically active major metabolite keto-darolutamide (Figure 1) . 12, 39 Darolutamide and its active metabolite have been shown to inhibit testosterone-induced translocation of AR to the nucleus, thus decreasing activation of genes required for the growth and survival of PC cells. 12 The proposed mechanism of action of darolutamide is shown in Figure 2 . In competitive AR binding assays (Table 2) , 12 ,40 darolutamide and its metabolite exhibited tighter binding to the AR than enzalutamide and apalutamide. 12 Darolutamide has demonstrated strong androgen inhibitory activity in in vitro and in vivo CRPC models. In vertebral cancer of the prostate (VCaP) cells (originally derived from a CRPC bone metastasis overexpressing AR) grown in the presence of a synthetic androgen, darolutamide and its major metabolite produced more potent suppression of androgen-induced cell growth compared with enzalutamide or apalutamide. 12 Antitumor activity was demonstrated in VCaP tumor-bearing castrated male nude mice treated with oral darolutamide (50 mg/kg) once or twice daily.
12 Point mutations within AR are common in CRPC and can drive resistance to ADT or even revert androgen inhibitors to agonists that promote activation/nuclear translocation of AR (Table 3) . 12 More specifically, F877L mutations within AR cause enzalutamide and apalutamide to become agonists, as do the W742L and T878A mutation for bicalutamide. 12 However, darolutamide and its major metabolite are full antagonists and retain their activity against known AR mutations shown to enable resistance to firstand second-generation ADTs.
12
ADT stimulation of the central nervous system (CNS) can result in increased serum testosterone levels. 12 An experiment in tumor-bearing intact nude mice showed that serum testosterone levels were significantly increased by enzalutamide but not with darolutamide. 12 Additionally, darolutamide has shown negligible blood-brain barrier (BBB) penetration. Quantitative whole body autoradiography in rats demonstrated low BBB penetration by darolutamide compared with enzalutamide (brain/blood ratio, 0.079 for darolutamide vs. 0.807 for enzalutamide). 41 Studies in mice also showed low brain/plasma ratios by darolutamide and its metabolite (0.019-0.039 and 0.019-0.028, respectively) compared with enzalutamide and apalutamide (0.27 and 0.62, respectively). 12 Together these results are in agreement with observations to date in darolutamide-treated patients. The observed limited BBB penetration by darolutamide may reduce the risk of CNS-related AEs such as seizures in patients with CRPC.
12,42
Clinical Study Data
Clinical studies with darolutamide include 2 completed phase I and II studies (ARADES, NCT01429064, Safety and Tolerability 42 A decrease in PSA from baseline of > 50% was observed in 71% of patients at 12 weeks, and anticancer activity was observed for all doses of darolutamide tested. 42 Soft tissue and bone lesion data showed promising results, with the chemotherapy-naive and CYP17i-naive patients showing the highest response to darolutamide treatment. 42, 43 The combined population long-term data for PSA progression in CT-and CYP17i-naive men with mCRPC are shown in Figure 3 . 44 AEs included fatigue or asthenia, back pain, arthralgia, pain, and constipation; most (91%) were grade 1/2. Treatment-related AEs occurred in 35% of patients and included fatigue, hot flashes, decreased appetite, diarrhea, and headache. No seizures were reported during the trial. 42 The ARAFOR phase I, multicenter study evaluated the PK of oral tablet darolutamide and the effect of food on absorption in chemotherapy-naive men with progressive mCRPC; preliminary long-term safety, tolerability, and antitumor activity was assessed in the open-label extension, during which patients received 600-mg darolutamide capsules 2 times per day. 45 A decrease in PSA from baseline > 50% was observed in 83% (25 of 30) of patients (Figure 4) . 45 The median time to PSA progression was 54 weeks (95% confidence interval [CI], 23 weeks to not reported), and the median time to radiographic progression was 66 weeks (95% CI, 41-79 weeks). At 12 weeks, the median serum testosterone level (0.60 nmol/L) was lower than that observed at baseline (0.80 nmol/L; P ¼ .5). 45 Adverse events, mostly grade 1/2, were reported in 73% (22 of 30) of patients and included fatigue and nausea in 4 patients. 45 Treatment-related AEs reported in 6 patients included fatigue, decreased appetite, headache, abdominal pain, solar dermatitis, tinnitus, and dysgeusia (all grade 1). There were no reports of seizures. These results demonstrated that darolutamide was well tolerated and exhibited antitumor activity against mCRPC. 45 ARAMIS is an international, randomized, double-blind, placebocontrolled, phase III clinical study examining the safety and efficacy of darolutamide in men with nmCRPC and will assess whether the addition of darolutamide to ADT delays the time to metastasis compared with placebo plus ADT (enrollment, N ¼ 1509). 39 The primary outcome measure is metastasis-free survival. Secondary outcomes include OS, time to first symptomatic skeletal event, time to initiation of first cytotoxic chemotherapy, and time to pain progression. ARASENS is a large (N ¼ 1300, target enrollment), international, randomized, phase III clinical study evaluating the safety and efficacy of darolutamide in men with mHSPC in addition to ADT and chemotherapy. The objective of ARASENS is to determine whether the addition of darolutamide to ADT and docetaxel chemotherapy significantly prolongs OS compared with placebo plus ADT and docetaxel in patients with mHSPC.
A phase II, randomized, open-label study will assess the safety and efficacy of oral darolutamide versus ADT with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists in men with hormone-naive PC (NCT02972060). The main study outcome is PSA response rate at 6 months compared with baseline. Health-related quality of life (HRQoL) will also be assessed.
Discussion
The ultimate goal of treatment is to cure PC or reduce the risk of progression from nonmetastatic to metastatic disease. If the disease is already metastatic, then the goal is to prolong OS. AR antagonists have demonstrated good antitumor efficacy to date in patients with mCRPC, and recently, significant increases in metastasis-free survival versus placebo have been shown with enzalutamide and apalutamide treatment. In addition, the ongoing ARAMIS trial will determine whether darolutamide will extend metastasis-free survival in men with nmCRPC. Moreover, several clinical trials are underway to assess the efficacy of AR antagonists with ADT in extending OS in men with mHSPC.
In addition to delaying the symptom and disease progression, another important consideration during the treatment of PC is preventing the deterioration of HRQoL. Both disease progression and adverse effects of treatment can lead to decreased HRQoL. 46 Although current safety data show that AR antagonists are generally well tolerated, CNS-related AEs, including fatigue, cognitive changes (memory impairment, amnesia, and disturbances in attention) and seizures, have been observed with some AR antagonists. 31, 36 Such AEs can have a negative impact on a patient's QoL, particularly in elderly patients who are more prone to falls and cognitive impairment such as dementia. 47 PC most often affects older men, a population that may not be able to tolerate certain treatment options because of comorbidities or treatment AEs, and there is currently no consensus regarding the best treatment strategy for these patients. [48] [49] [50] In addition, fatigue is a common adverse effect of PC and associated treatments that can also negatively impact QoL. 47 It is encouraging to note that patients with progressive mCRPC after docetaxel treatment who were then subsequently treated with abiraterone acetate and prednisone showed improvements in patient-reported fatigue. 47 In contrast, fatigue was among the AEs most commonly reported with enzalutamide treatment. 34 There are few options for men who develop mutations to current AR-targeting treatments. Preclinical and early-stage clinical studies indicate that darolutamide is an effective and generally well-tolerated anti-PC therapy, 39 with a favorable safety profile. 51 Phase II studies of darolutamide in patients with progressive mCRPC demonstrated high antitumor activity, with the highest activity in patients without prior chemotherapy or prior CYP17i exposure. 51 Importantly, darolutamide and its major metabolite act as antagonists, binding to and inhibiting both wild-type and mutant AR. 12 Darolutamide and its major metabolite retain their activity against AR mutations currently known to cause resistance to first-and second-generation AR antagonists, including the F877L mutation, which drives resistance to enzalutamide and apalutamide, as well as the W742L mutation, which causes resistance to bicalutamide.
12
A further distinction between darolutamide and other AR antagonists is that it has shown negligible penetration of the BBB, 12, 41 which suggests the potential for fewer CNS-related AEs such as fatigue, cognitive impairment, and seizures. Patients with preexisting CNS events or receiving CNS medications were not excluded in trials of darolutamide, 33, 34, 37 and thus far, in phase I/II trials, there have been no reports of seizures during darolutamide treatment.
42,45
Conclusion AR antagonists have demonstrated good antitumor efficacy in patients with mCRPC, and enzalutamide and apalutamide have recently shown efficacy in extending metastasis-free survival in patients with nmCRPC. The ongoing ARAMIS trial is evaluating whether treatment with darolutamide will prevent or delay the time for development of mCRPC in men with nmCRPC. Early clinical studies and preclinical data suggest that darolutamide has a favorable AE profile with fewer CNS-related events possibly due to limited penetration of the BBB. Additionally, darolutamide and its major metabolite retain their activity against AR mutations currently known to cause resistance to first-and second-generation AR antagonists. Darolutamide could offer an alternative for the treatment of advanced PC in elderly men who may not be able to tolerate the adverse events associated with other treatments. 47 The promising preclinical and early clinical findings with darolutamide require confirmation in phase III trials.
